| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Peripheral-blood stem cells versus bone marrow from unrelated donors.
|
N Engl J Med
|
2012
|
6.30
|
|
2
|
Lenalidomide after stem-cell transplantation for multiple myeloma.
|
N Engl J Med
|
2012
|
6.24
|
|
3
|
Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial.
|
Ann Intern Med
|
2003
|
3.92
|
|
4
|
Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma.
|
Blood
|
2009
|
3.84
|
|
5
|
Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma.
|
J Clin Oncol
|
2009
|
3.47
|
|
6
|
Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies.
|
JAMA
|
2011
|
3.45
|
|
7
|
Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients.
|
Biol Blood Marrow Transplant
|
2005
|
2.82
|
|
8
|
In vitro engagement of CD3 and CD28 corrects T cell defects in chronic lymphocytic leukemia.
|
J Immunol
|
2005
|
2.38
|
|
9
|
Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma.
|
J Clin Oncol
|
2007
|
2.34
|
|
10
|
Unrelated donor transplants in adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission.
|
Blood
|
2008
|
2.34
|
|
11
|
Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure.
|
J Clin Oncol
|
2010
|
2.31
|
|
12
|
Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma.
|
Blood
|
2003
|
2.31
|
|
13
|
Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma.
|
Blood
|
2004
|
2.28
|
|
14
|
Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors.
|
J Clin Oncol
|
2005
|
2.15
|
|
15
|
Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma.
|
Biol Blood Marrow Transplant
|
2008
|
2.15
|
|
16
|
Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia.
|
J Clin Oncol
|
2010
|
2.07
|
|
17
|
TERC and TERT gene mutations in patients with bone marrow failure and the significance of telomere length measurements.
|
Blood
|
2008
|
1.99
|
|
18
|
Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation.
|
Cancer
|
2008
|
1.97
|
|
19
|
Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation.
|
Blood
|
2010
|
1.97
|
|
20
|
Impending challenges in the hematopoietic stem cell transplantation physician workforce.
|
Biol Blood Marrow Transplant
|
2009
|
1.97
|
|
21
|
Classifying cytogenetics in patients with acute myelogenous leukemia in complete remission undergoing allogeneic transplantation: a Center for International Blood and Marrow Transplant Research study.
|
Biol Blood Marrow Transplant
|
2011
|
1.88
|
|
22
|
Salvage second hematopoietic cell transplantation in myeloma.
|
Biol Blood Marrow Transplant
|
2013
|
1.80
|
|
23
|
Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study.
|
J Clin Oncol
|
2010
|
1.74
|
|
24
|
Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS).
|
Blood
|
2013
|
1.71
|
|
25
|
Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia.
|
Blood
|
2009
|
1.70
|
|
26
|
Outcome of transplantation for myelofibrosis.
|
Biol Blood Marrow Transplant
|
2009
|
1.68
|
|
27
|
Significant improvement in survival after allogeneic hematopoietic cell transplantation during a period of significantly increased use, older recipient age, and use of unrelated donors.
|
J Clin Oncol
|
2013
|
1.66
|
|
28
|
Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation.
|
J Clin Oncol
|
2006
|
1.63
|
|
29
|
Risk factors for acute graft-versus-host disease after human leukocyte antigen-identical sibling transplants for adults with leukemia.
|
J Clin Oncol
|
2008
|
1.63
|
|
30
|
The National Marrow Donor Program's Symposium on Hematopoietic Cell Transplantation in 2020: a health care resource and infrastructure assessment.
|
Biol Blood Marrow Transplant
|
2011
|
1.60
|
|
31
|
Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality.
|
J Clin Oncol
|
2013
|
1.59
|
|
32
|
Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting.
|
Blood
|
2008
|
1.59
|
|
33
|
Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial.
|
Blood
|
2004
|
1.58
|
|
34
|
Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI.
|
Blood
|
2013
|
1.54
|
|
35
|
Unrelated donor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell transplantation after nonmyeloablative conditioning: the effect of postgrafting mycophenolate mofetil dosing.
|
Biol Blood Marrow Transplant
|
2006
|
1.54
|
|
36
|
Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation.
|
J Clin Oncol
|
2013
|
1.53
|
|
37
|
Race and socioeconomic status influence outcomes of unrelated donor hematopoietic cell transplantation.
|
Biol Blood Marrow Transplant
|
2009
|
1.52
|
|
38
|
Fludarabine and 2-Gy TBI is superior to 2 Gy TBI as conditioning for HLA-matched related hematopoietic cell transplantation: a phase III randomized trial.
|
Biol Blood Marrow Transplant
|
2013
|
1.51
|
|
39
|
Standardization of terminology for episodes of hematopoietic stem cell patient transplant care.
|
Biol Blood Marrow Transplant
|
2013
|
1.47
|
|
40
|
Improved outcome with busulfan, melphalan and thiotepa conditioning in autologous hematopoietic stem cell transplant for relapsed/refractory Hodgkin lymphoma.
|
Leuk Lymphoma
|
2013
|
1.46
|
|
41
|
Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia.
|
Blood
|
2008
|
1.42
|
|
42
|
Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience.
|
Br J Haematol
|
2008
|
1.31
|
|
43
|
Trends in use of and survival after autologous hematopoietic cell transplantation in North America, 1995-2005: significant improvement in survival for lymphoma and myeloma during a period of increasing recipient age.
|
Biol Blood Marrow Transplant
|
2013
|
1.31
|
|
44
|
Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission.
|
Leuk Res
|
2004
|
1.30
|
|
45
|
Unrelated donor reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma.
|
Biol Blood Marrow Transplant
|
2009
|
1.28
|
|
46
|
Who is the better donor for older hematopoietic transplant recipients: an older-aged sibling or a young, matched unrelated volunteer?
|
Blood
|
2013
|
1.27
|
|
47
|
Comparison of short-term response and long-term outcomes after initial systemic treatment of chronic graft-versus-host disease.
|
Biol Blood Marrow Transplant
|
2010
|
1.25
|
|
48
|
Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease.
|
Blood
|
2009
|
1.25
|
|
49
|
Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?
|
Blood
|
2012
|
1.23
|
|
50
|
A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR.
|
Biol Blood Marrow Transplant
|
2009
|
1.22
|
|
51
|
Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia.
|
Br J Haematol
|
2007
|
1.20
|
|
52
|
Central nervous system failure in patients with chronic myelogenous leukemia lymphoid blast crisis and Philadelphia chromosome positive acute lymphoblastic leukemia treated with imatinib (STI-571).
|
Leuk Lymphoma
|
2004
|
1.12
|
|
53
|
Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies.
|
Biol Blood Marrow Transplant
|
2010
|
1.12
|
|
54
|
Pregnancy after hematopoietic cell transplantation: a report from the late effects working committee of the Center for International Blood and Marrow Transplant Research (CIBMTR).
|
Biol Blood Marrow Transplant
|
2010
|
1.11
|
|
55
|
Second unrelated donor hematopoietic cell transplantation for primary graft failure.
|
Biol Blood Marrow Transplant
|
2010
|
1.06
|
|
56
|
Successful stem cell remobilization using plerixafor (mozobil) plus granulocyte colony-stimulating factor in patients with non-hodgkin lymphoma: results from the plerixafor NHL phase 3 study rescue protocol.
|
Biol Blood Marrow Transplant
|
2009
|
1.05
|
|
57
|
A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma.
|
Blood
|
2002
|
1.03
|
|
58
|
A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma.
|
Br J Haematol
|
2012
|
1.02
|
|
59
|
Hematopoietic cell transplantation in 2020: summary of year 2 recommendations of the National Marrow Donor Program's System Capacity Initiative.
|
Biol Blood Marrow Transplant
|
2012
|
0.98
|
|
60
|
Clinical scale expanded adult pluripotent stem cells prevent graft-versus-host disease.
|
Cell Immunol
|
2008
|
0.98
|
|
61
|
Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.
|
Biol Blood Marrow Transplant
|
2012
|
0.97
|
|
62
|
Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant.
|
Biol Blood Marrow Transplant
|
2008
|
0.97
|
|
63
|
Outcomes of allogeneic hematopoietic cell transplantation for adolescent and young adults compared with children and older adults with acute myeloid leukemia.
|
Biol Blood Marrow Transplant
|
2011
|
0.95
|
|
64
|
Abandonment of high-dose chemotherapy/hematopoietic cell transplants for breast cancer following negative trial results.
|
Health Serv Res
|
2011
|
0.94
|
|
65
|
MSCs in hematopoietic cell transplantation.
|
Biol Blood Marrow Transplant
|
2011
|
0.93
|
|
66
|
Explaining family caregiver role strain following autologous blood and marrow transplantation.
|
J Psychosoc Oncol
|
2006
|
0.92
|
|
67
|
Pure red cell aplasia associated with parvovirus B19 infection occurring late after allogeneic bone marrow transplantation.
|
Am J Hematol
|
2004
|
0.89
|
|
68
|
A phase III, randomized, double-blind, placebo-controlled, study of iseganan for the reduction of stomatitis in patients receiving stomatotoxic chemotherapy.
|
Leuk Res
|
2004
|
0.89
|
|
69
|
Novel H1N1 influenza in hematopoietic stem cell transplantation recipients: two centers' experiences.
|
Biol Blood Marrow Transplant
|
2010
|
0.89
|
|
70
|
The potential of mesenchymal stromal cells as a novel cellular therapy for multiple sclerosis.
|
Immunotherapy
|
2012
|
0.88
|
|
71
|
Autologous and allogeneic transplantation for burkitt lymphoma outcomes and changes in utilization: a report from the center for international blood and marrow transplant research.
|
Biol Blood Marrow Transplant
|
2012
|
0.88
|
|
72
|
Transplanted CD34(+) cell dose is associated with long-term platelet count recovery following autologous peripheral blood stem cell transplant in patients with non-Hodgkin lymphoma or multiple myeloma.
|
Biol Blood Marrow Transplant
|
2010
|
0.87
|
|
73
|
Outcomes of hematologic malignancies after unrelated donor hematopoietic cell transplantation according to place of residence.
|
Biol Blood Marrow Transplant
|
2009
|
0.86
|
|
74
|
Safety and efficacy of upfront plerixafor + G-CSF versus placebo + G-CSF for mobilization of CD34(+) hematopoietic progenitor cells in patients ≥60 and <60 years of age with non-Hodgkin's lymphoma or multiple myeloma.
|
Am J Hematol
|
2013
|
0.84
|
|
75
|
Pretransplantation consolidation chemotherapy decreases leukemia relapse after autologous blood and bone marrow transplants for acute myelogenous leukemia in first remission.
|
Biol Blood Marrow Transplant
|
2006
|
0.84
|
|
76
|
Update in the epidemiology, prophylaxis, and treatment of fungal infections in patients with hematologic disorders.
|
Leuk Lymphoma
|
2004
|
0.84
|
|
77
|
Phase II trial of parathyroid hormone after double umbilical cord blood transplantation.
|
Biol Blood Marrow Transplant
|
2012
|
0.83
|
|
78
|
Extended mycophenolate mofetil and shortened cyclosporine failed to reduce graft-versus-host disease after unrelated hematopoietic cell transplantation with nonmyeloablative conditioning.
|
Biol Blood Marrow Transplant
|
2007
|
0.83
|
|
79
|
Drug resistance in B-cell chronic lymphocytic leukemia: predictable by in vitro evaluation with a multiparameter flow cytometric cytotoxicity assay.
|
Cytometry B Clin Cytom
|
2007
|
0.82
|
|
80
|
Allogeneic hematopoietic cell transplantation for advanced polycythemia vera and essential thrombocythemia.
|
Biol Blood Marrow Transplant
|
2012
|
0.82
|
|
81
|
Hematopoietic stem cell transplantation for myelofibrosis: where are we now?
|
Curr Opin Hematol
|
2013
|
0.81
|
|
82
|
Unrelated donor allogeneic transplantation after failure of autologous transplantation for acute myelogenous leukemia: a study from the center for international blood and marrow transplantation research.
|
Biol Blood Marrow Transplant
|
2013
|
0.81
|
|
83
|
Stem cell transplantation in patients with chronic myelogenous leukemia: when should it be used?
|
Mayo Clin Proc
|
2006
|
0.79
|
|
84
|
HLA-identical sibling allogeneic transplants versus chemotherapy in acute myelogenous leukemia with t(8;21) in first complete remission: collaborative study between the German AML Intergroup and CIBMTR.
|
Biol Blood Marrow Transplant
|
2007
|
0.79
|
|
85
|
CD25 expression distinguishes functionally distinct alloreactive CD4 CD134 (OX40) T-cell subsets in acute graft-versus-host disease.
|
Biol Blood Marrow Transplant
|
2004
|
0.79
|
|
86
|
Adult adherent stromal cells in the management of graft-versus-host disease.
|
Expert Opin Biol Ther
|
2014
|
0.78
|
|
87
|
Life-threatening adenovirus infections in the setting of the immunocompromised allogeneic stem cell transplant patients.
|
Adv Hematol
|
2010
|
0.78
|
|
88
|
Allogeneic stem cell transplantation for chronic myeloproliferative disorders and myelodysplastic syndromes: the question is "when?".
|
Mayo Clin Proc
|
2003
|
0.78
|
|
89
|
HLA DR15 antigen status does not impact graft-versus-host disease or survival in HLA-matched sibling transplantation for hematologic malignancies.
|
Biol Blood Marrow Transplant
|
2012
|
0.78
|
|
90
|
Comparative cost-effectiveness analysis of voriconazole and fluconazole for prevention of invasive fungal infection in patients receiving allogeneic hematopoietic cell transplants.
|
Am J Health Syst Pharm
|
2013
|
0.77
|
|
91
|
Dissection of the human multipotent adult progenitor cell secretome by proteomic analysis.
|
Stem Cells Transl Med
|
2013
|
0.77
|
|
92
|
Allogeneic hematopoietic cell transplant for prolymphocytic leukemia.
|
Biol Blood Marrow Transplant
|
2009
|
0.77
|
|
93
|
Management of life-threatening pulmonary leukostasis with single agent imatinib mesylate during CML myeloid blast crisis.
|
Haematologica
|
2004
|
0.77
|
|
94
|
Informal caregiving in Hematopoietic Blood and Marrow Transplant patients.
|
Eur J Oncol Nurs
|
2011
|
0.76
|
|
95
|
Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of imatinib treatment on remission induction and allogeneic stem cell transplantation.
|
Curr Oncol Rep
|
2006
|
0.76
|
|
96
|
A changing time: the International Society for Cellular Therapy embraces its industry members.
|
Cytotherapy
|
2010
|
0.75
|
|
97
|
Emergence of Cunninghamella as a pathogenic invasive mold infection in allogeneic transplant recipients.
|
Clin Lymphoma Myeloma Leuk
|
2013
|
0.75
|
|
98
|
Response to Letter from Demetrios S. Theodoropoulos, MD, DSc.
|
Biol Blood Marrow Transplant
|
2010
|
0.75
|